Skip to content

OÜ Kvatropharma

Registry code (registrikood) 12976249Private limited company (Osaühing)VAT EE101853538Activity (EMTAK 47731): Ravimite jaemüükActive

Tallinn, Harju County · Financial data: annual reports up to 2025; tax data up to 2026 Q3

Revenue (2025)
€6.2M
▲ 20.7% vs 2024
Profit before tax (2025)
-€46k
Employees, FTE (2025)
6
State taxes paid, last 4 quarters
€13k

Revenue, profit and employees, 2019–2025

€2.8M2019€3.5M2020€3.8M2021€4.2M2022€5.1M2023€5.1M2024€6.2M2025
YearRevenue (müügitulu)Operating profit (ärikasum)Net profitEquity (omakapital)Employees, FTE
2019€2,798,156-€299,719-€321,585-€842,05622
2020€3,538,776-€121,998-€146,396-€988,45224
2021€3,794,742€305,305€280,971-€707,4811
2022€4,208,233€68,804€42,611-€664,8713
2023€5,051,748€332,291€303,430€23,5244
2024€5,140,835-€87,302-€88,151-€64,6274
2025€6,206,906-€45,313-€46,046-€110,6736

Balance sheet summary

YearCashTotal assetsCurrent liabilitiesNon-current liabilitiesEquity
2019€49,395€549,865€1,391,921—-€842,056
2020€71,065€741,825€1,730,277—-€988,452
2021€51,285€660,382€1,367,863—-€707,481
2022€340,935€1,017,500€1,682,371—-€664,871
2023€586,909€1,373,443€1,349,919—€23,524
2024€118,450€888,076€952,703—-€64,627
2025€214,959€1,183,958€1,294,631—-€110,673

Calculated ratios

Net profit margin = net profit ÷ revenue. Equity ratio = equity ÷ total assets. Seedata sources & methodology for how each figure is derived.

Quarterly tax and turnover data (EMTA)

QuarterState taxes paidWage taxesTurnoverEmployees
2022 Q1€0€4,587€1,007,0174
2022 Q2€1,214€5,987€909,7625
2022 Q3€0€13,986€965,8777
2022 Q4€901€15,481€1,229,6716
2023 Q1€1,811€14,604€1,205,3756
2023 Q2€6,880€16,664€1,237,0508
2023 Q3€12,170€18,202€1,106,4368
2023 Q4€11,068€23,447€1,386,6367
2024 Q1€13,349€22,999€1,354,6517
2024 Q2€2,127€25,441€1,265,42011
2024 Q3€5,445€24,986€1,210,85013
2024 Q4€6,853€23,415€1,355,04124
2025 Q1€1,576€25,521€1,381,55424
2025 Q2€0€20,556€1,539,76124
2025 Q3€1,271€19,217€1,374,03824
2025 Q4€1,246€20,757€1,645,64027
2026 Q1€0€20,525€1,798,51425
2026 Q2€0€13,912€1,719,53827
2026 Q3€12,006€16,464€1,926,33429

Source: EMTA quarterly published data, as of 10 October 2026. Covers state taxes and wage taxes actually paid and turnover and employee counts as declared by the company, not the annual report figures above.

About this data

In the 2025 financial year (period 1 January 2025–31 December 2025), OÜ Kvatropharma reported revenue of €6,206,906.

The company recorded a net loss of €46,046 in the 2025 financial year.

Revenue increased by 20.7% from €5,140,835 in 2024 to €6,206,906 in 2025.

Revenue grew at a compound annual rate of 14.2% between 2019 and 2025.

Equity accounted for -9.3% of total assets of €1,183,958 at the end of the 2025 reporting period.

With 6 full-time-equivalent employees in 2025, revenue per employee was €1,034,484.

Across the 4 most recent quarters declared to EMTA, up to Q3 2026, OÜ Kvatropharma reported €7,090,026 in turnover.

EMTA recorded 29 employees for the quarter ending Q3 2026, compared with 6 full-time-equivalent employees in the 2025 annual report.

Browse

Source

Source: Estonian e-Business Register open data (Centre of Registers and Information Systems, RIK), licence CC BY-SA 4.0, modified; Estonian Tax and Customs Board (EMTA) quarterly data. Downloaded 2026-11-16. This is not an official register extract — see ariregister.rik.ee.

Company data on this site is available under CC BY-SA 4.0.

To request a correction or the removal of this page, use the contact form. Removal requests are handled within 30 days, no justification required.